https://www.live-feeds.com/feed/novo-nordisk-stops-two-cardiovascular-trials-of-drug-aimed-at-lowering-inflammationContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-nordisk-stops-two-cardiovascular-trials-of-drug-aimed-at-lowering-inflammationhttps://www.live-feeds.com/feed/novo-nordisk-stops-two-cardiovascular-trials-of-drug-aimed-at-lowering-inflammation#u61946Tue, 08 Sep 2026 22:42:14 +0000Novo Nordisk stopped two phase 3 cardiovascular trials for ziltivekimab, a drug designed to reduce inflammation. The terminated studies focused on heart failure and chronic kidney disease. This setback limits the company's ability to expand its growth beyond its current obesity medication portfolio. The company had positioned the ziltivekimab program as a potential blockbuster, but the early termination of these studies diminishes those prospects.Why it mattersZiltivekimab targets inflammation to treat cardiovascular issues. Diversifying beyond obesity treatments is a strategic priority f